[
  {
    "ts": "2025-10-13T16:10:04+00:00",
    "headline": "Why Amgen (AMGN) Could Beat Earnings Estimates Again",
    "summary": "Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finance.yahoo.com/news/why-amgen-amgn-could-beat-161004298.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "4c3d550c-636e-3b10-b98d-7c3e10963d94",
      "content": {
        "id": "4c3d550c-636e-3b10-b98d-7c3e10963d94",
        "contentType": "STORY",
        "title": "Why Amgen (AMGN) Could Beat Earnings Estimates Again",
        "description": "",
        "summary": "Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
        "pubDate": "2025-10-13T16:10:04Z",
        "displayTime": "2025-10-13T16:10:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PIdvgNQlfpuBODSIZCqYyg--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sAMTWSt0tSP35kyVmwadNw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-amgen-amgn-could-beat-161004298.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-amgen-amgn-could-beat-161004298.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-13T12:43:46+00:00",
    "headline": "Amgen Repatha Phase 3 Trial Meets Dual Primary Endpoints for Primary Cardiovascular Prevention",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that Repatha (evolocumab) significantly reduced the risk of Major Adverse Cardiovascular Events/MACE in high-risk individuals without a prior history of heart attack or […]",
    "url": "https://finance.yahoo.com/news/amgen-repatha-phase-3-trial-124346508.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "d947935d-ea74-3f4b-b084-cfc3d5fddee0",
      "content": {
        "id": "d947935d-ea74-3f4b-b084-cfc3d5fddee0",
        "contentType": "STORY",
        "title": "Amgen Repatha Phase 3 Trial Meets Dual Primary Endpoints for Primary Cardiovascular Prevention",
        "description": "",
        "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that Repatha (evolocumab) significantly reduced the risk of Major Adverse Cardiovascular Events/MACE in high-risk individuals without a prior history of heart attack or […]",
        "pubDate": "2025-10-13T12:43:46Z",
        "displayTime": "2025-10-13T12:43:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Amgen Repatha Phase 3 Trial Meets Dual Primary Endpoints for Primary Cardiovascular Prevention",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fl9k_iPg0JyfVI.qZJRd8A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RgojEqpZ8ITlaPGpQimL8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-repatha-phase-3-trial-124346508.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-repatha-phase-3-trial-124346508.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-13T03:32:42+00:00",
    "headline": "Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)",
    "summary": "Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers.",
    "url": "https://finance.yahoo.com/news/reflecting-therapeutics-stocks-q2-earnings-033242997.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "a2920413-5752-3337-b522-a64857f8cdc7",
      "content": {
        "id": "a2920413-5752-3337-b522-a64857f8cdc7",
        "contentType": "STORY",
        "title": "Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)",
        "description": "",
        "summary": "Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers.",
        "pubDate": "2025-10-13T03:32:42Z",
        "displayTime": "2025-10-13T03:32:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/85fc5540fd7647d2927a8cba48ff7e92",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "AMGN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cVRDvNeMN6SVWgnyfhcabA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/85fc5540fd7647d2927a8cba48ff7e92.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/khfuGqTIKrJ0BdS6OOusRA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/85fc5540fd7647d2927a8cba48ff7e92.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/reflecting-therapeutics-stocks-q2-earnings-033242997.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/reflecting-therapeutics-stocks-q2-earnings-033242997.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]